Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.
Expanded conditional approval allows drugs that are undergoing their final clinical trial assessment and are supported by ...
New Scientist on MSN2d
The 13 drugs and supplements that could slow brain ageingHydrocortisone and testosterone are just two of 13 drugs and supplements that could lessen the impact of genes that ...
Target Indications Include Microcystic Lymphatic Malformations, Venous Malformations and AngiofibromasProprietary Invisicare ...
Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic ...
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP < ...
Medical Device Network on MSN15d
Teleflex to split into two separate entitiesTeleflex is splitting its business into two independently traded entities, with a completion date set for mid-2026 ...
ISM001-055 was shown to have attenuated cellular senescence through the suppression of various aging processes, thus showing potential as a senomorphic drug.
Teleflex management announced a significant acquisition and business split, but the market reacted negatively. Read why I ...
eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback